Abstract:Background: PB-201, a partial, pancreas/liver-dual glucokinase activator, showed good tolerance and glycaemic effects in multinational studies. We aimed to determine its optimal dose and to evaluate its safety, pharmacokinetics, and pharmacodynamics in Chinese patients with type 2 diabetes. Methods: In this double-blind, randomised, four-period, crossover, phase 1 trial in China (NCT03973515), adult patients with drug-naive type 2 diabetes were randomised (1:1:1:1) to four sequence groups using a computer-generated randomisation table. In each period, they received oral placebo or PB-201 (50+50, 100+50, or 100+100 mg split doses) for 7 days. Investigators and patients were masked to treatment assignment. The primary endpoints were safety and pharmacokinetics. Continuous glucose monitoring was used to delineate the glucose excursion profile.Findings: Between July 18, 2019 and September 05, 2019, 16 patients were randomised. PB-201 showed a dose-proportional pharmacokinetic profile and dose-dependent lowering of blood glucose, similar to findings in non-Chinese populations. PB-201 at 100+50 and 100+100 mg increased mean time in range (49·210% [standard deviation 27], 56·130% [25], and 63·330% [20] with three doses, respectively) versus placebo (49·380% [27]) and reduced estimated glycated haemoglobin from baseline (−0·5445% [1·654], −1·063% [1·236], and −1·888% [1·381] vs −0·581% [1·200]). All treatment-emergent adverse events were mild. No patients had hypoglycaemia with venous/capillary glucose <3·9 mmol/L or nocturnal hypoglycaemia.Interpretation: PB-201 100 mg twice daily is identified as the optimal dose, which shows promising glucose-lowering effects and low risks of hypoglycaemia and other side effects. Further investigation of PB-201 100 mg twice daily in confirmatory trials is warranted.Trial Registration: This trial was registered with ClinicalTrials.gov, number NCT03973515.Funding: PegBio.Declaration of Interest: YD and MX are employees of PegBio, and HZ is an ex-employee of PegBio. LJ has received fees for lecture presentations from AstraZeneca, Merck, Novartis, Lilly, Roche, Sanofi-Aventis and Takeda; consulting fees from AstraZeneca, Merck, Novartis, Lilly, Roche, Sanofi-Aventis and Takeda; and grants/research support from AstraZeneca, Bristol-Myers Squibb, Merck, Novartis and Sanofi-Aventis. All other authors declare no competing interests.Ethical Approval: The study protocol and informed consent information were approved by the ethics committee at Peking University Third Hospital.

Study on tolerance of subcutaneous injection in single dose of recombinated human glucagon-like peptide-1 in Chinese healthy volunteers

Pharmacokinetics, Pharmacodynamics And Tolerability Of Single Dose Of Recombinant Glucagon-Like Peptide-1 Receptor Agonist In Healthy Chinese Subjects

Pharmacokinetics and safety profiles of beinaglutide injection, a recombinant human GLP-1, in adults with overweight/obesity: results from a phase I clinical trial

Pharmacokinetics Study of rhGLP1(7-36) in Type 2 Diabetes Patients

Pharmacokinetics, Pharmacodynamics, and Bioequivalence Study of SciLin TMR Recombinant Human Insulin Injection Preparation

Evaluating the bioequivalence and safety of liraglutide injection versus Victoza® in healthy Chinese subjects: a randomized, open, two-cycle, self-crossover phase I clinical trial

A phase 1, randomized, double‐blind, placebo‐controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TG103 Injection in Participants Who Are Overweight or Obese: a Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Phase 1b Study

Safety, pharmacokinetics and pharmacodynamics of multiple‐dose noiiglutide (SHR20004), a novel GLP‐1 receptor agonist, in Chinese obese subjects without diabetes mellitus

Pharmacokinetics and Preliminary Pharmacodynamics of Single- and Multiple-dose Lyophilized Recombinant Glucagon-like Peptide-1 Receptor Agonist (Re-4) in Chinese Patients with Type 2 Diabetes Mellitus

A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes

Safety, Tolerability and Pharmacokinetics of Single Dose Polyethylene Glycolated Exenatide Injection (PB-119) in Healthy Volunteers

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Glucokinase Activator PB-201 and Its Effects on the Glucose Excursion Profile in Drug-Naive Chinese Patients with Type 2 Diabetes: A Randomised Controlled, Crossover Trial

Population Pharmacokinetics of Lyophilized Recombinant Glucagon-Like Peptide-1 Receptor Agonist (recombinant Exendin-4, Re-4) in Chinese Patients with Type 2 Diabetes Mellitus

Characterization of lymphocytes invading experimental tumors.

Bioavailability of Orally Administered Rhgm-Csf: a Single-Dose, Randomized, Open-Label, Two-Period Crossover Trial.

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Glucokinase Activator PB-201 and Its Effects on the Glucose Excursion Profile in Drug-Naïve Chinese Patients with Type 2 Diabetes: a Randomised Controlled, Crossover, Single-Centre Phase 1 Trial

Safety, tolerability, pharmacokinetic, pharmacodynamic and immunogenicity profiles of Exendin‐4‐IgG4‐Fc in healthy subjects: A phase 1, single‐centre, randomized, double‐blind, dose escalation study

Pharmacokinetics, Pharmacodynamics, and Safety of Dulaglutide After Single or Multiple Doses in Chinese Healthy Subjects and Patients with T2DM: A Randomized, Placebo-Controlled, Phase I Study

A Health Technology Assessment Based on Chinese Guidelines: Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Type 2 Diabetes Complicated with Cardiovascular Disease

Comparison of the safety and clinical efficacy of glucagon-like peptide-1 receptor agonist and α-glucosidase inhibitor among Chinese people with type 2 diabetes